Eplerenone

References

• Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro
  • M. de Gasparo, U. Joss, H. P. Ramjoué, S. E. Whitebread, H. Haenni, L. Schenkel, C. Kraehenbuehl, M. Biollaz, J. Grob, J. Schmidlin, J. Pharmacol. Exp. Ther. 1987, 240, 650.
• Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats
  • E. R. Blasi, R. Rocha, A. E. Rudolph, E. A. G. Blomme, M. L. Polly, E. G. Mcmahon, Kidney Int. 2003, 63, 1791.
• Effects of Long-Term Monotherapy With Eplerenone, a Novel Aldosterone Blocker, on Progression of Left Ventricular Dysfunction and Remodeling in Dogs With Heart Failure
  • G. Suzuki, H. Morita, T. Mishima, V. G. Sharov, A. Todor, E. J. Tanhehco, A. E. Rudolph, E. G. McMahon, S. Goldstein, H. N. Sabbah, Circulation 2002, 106, 2967.
• Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts
  • N. Kobayashi, K. Yoshida, S. Nakano, T. Ohno, T. Honda, Y. Tsubokou, H. Matsuoka, Hypertension 2006, 47, 671.
• Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone (a review)
  • X. Hu, S. Li, E. G. McMahon, D. S. Lala, A. E. Rudolph, Mini Rev. Med. Chem. 2005, 5, 709.
• A validated SPE-LC-MS/MS assay for Eplerenone and its hydrolyzed metabolite in human urine
  • J. Y. Zhang, D. M. Fast, A. P. Breau, J. Pharm. Biomed. Anal. 2003, 31, 103.
• Stability-indicating RP-HPLC method for analysis of eplerenone in the bulk drug and in a pharmaceutical dosage form
  • V. P. RaneRelated, K. R. PatilRelated, J. N. SangshettiRelated, R. D. YeoleRelated, D. B. Shinde, Acta Chromatogr. 2009, 21, 619.